TY - JOUR
T1 - Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies
AU - for the Movement Disorder Society–Endorsed Progressive Supranuclear Palsy Study Group
AU - Respondek, Gesine
AU - Grimm, Max Joseph
AU - Piot, Ines
AU - Arzberger, Thomas
AU - Compta, Yaroslau
AU - Englund, Elisabet
AU - Ferguson, Leslie W.
AU - Gelpi, Ellen
AU - Roeber, Sigrun
AU - Giese, Armin
AU - Grossman, Murray
AU - Irwin, David J.
AU - Meissner, Wassilios G.
AU - Nilsson, Christer
AU - Pantelyat, Alexander
AU - Rajput, Alex
AU - van Swieten, John C.
AU - Troakes, Claire
AU - Höglinger, Günter U.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4-repeat (4R)-tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. Objectives: To validate the accuracy of these clinical criteria for “probable 4R-tauopathy” to predict underlying 4R-tauopathy pathology. Methods: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). Results: We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of “probable 4R-tauopathy” was 10% and 99% in the first year and 59% and 88% at final record. Conclusions: The new diagnostic category “probable 4R-tauopathy” showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers.
AB - Background: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4-repeat (4R)-tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. Objectives: To validate the accuracy of these clinical criteria for “probable 4R-tauopathy” to predict underlying 4R-tauopathy pathology. Methods: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). Results: We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of “probable 4R-tauopathy” was 10% and 99% in the first year and 59% and 88% at final record. Conclusions: The new diagnostic category “probable 4R-tauopathy” showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers.
KW - corticobasal degeneration
KW - diagnostic criteria
KW - Four-repeat tauopathies
KW - progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85073963867&partnerID=8YFLogxK
U2 - 10.1002/mds.27872
DO - 10.1002/mds.27872
M3 - Article
C2 - 31571273
AN - SCOPUS:85073963867
SN - 0885-3185
VL - 35
SP - 171
EP - 176
JO - Movement Disorders
JF - Movement Disorders
IS - 1
ER -